SLU-PP-332: The Exercise Mimetic That Works In Mice
A small molecule that makes sedentary mice run 50% farther. No human data yet. But the mechanism is real — and different from everything else.
Quick read: SLU-PP-332 is a small-molecule ERR-α agonist discovered in 2023 that produces exercise-like adaptations in skeletal muscle. In sedentary mice: 50% increase in running endurance, 10–12% body fat reduction, improved insulin sensitivity. No human trials yet. Think of it as a scientific curiosity that may or may not become a drug — but the mechanism is genuinely novel.
The discovery
In August 2023, Kyle Stephens and colleagues at Saint Louis University published a characterization of SLU-PP-332, a small molecule they developed as a pan-ERR (estrogen-related receptor) agonist.
The initial publication included a striking result: sedentary mice given SLU-PP-332 ran 50% farther on a treadmill than untreated controls. Their muscles showed increased mitochondrial density, fiber-type shifts toward oxidative fibers, and metabolic changes typically only seen in trained animals.
Within months, additional papers showed:
- 10–12% body fat reduction in obese mice on high-fat diets, without reduced food intake
- Improved insulin sensitivity and glucose handling
- Enhanced exercise performance when combined with actual exercise
- No cardiac hypertrophy (a common failure mode for earlier ERR drugs)
The exercise-mimetic headlines followed. "Exercise in a pill" was inevitable marketing.
What ERR-α actually does
ERR-α, ERR-β, and ERR-γ are orphan nuclear receptors — they don't have a well-defined natural ligand like estrogen or testosterone. Instead, they respond to cellular metabolic cues and transcriptionally drive programs related to:
- Mitochondrial biogenesis (making more mitochondria)
- Fatty acid oxidation (burning fat for fuel)
- Oxidative phosphorylation (cellular energy production efficiency)
- Muscle fiber typing (slow-twitch/oxidative versus fast-twitch/glycolytic)
When you exercise — particularly endurance training — you activate ERR receptors endogenously. This drives the adaptations that make trained muscle different from untrained: more mitochondria, better fat burning, slower fatigue.
SLU-PP-332 activates this transcriptional program without the exercise stimulus. That's the pharmacological point.
Why this is different from AICAR
You may have heard of AICAR, the older "exercise mimetic" that also made sedentary mice run longer.
Key differences:
| Property | SLU-PP-332 | AICAR |
|---|---|---|
| Target | ERR-α, β, γ | AMPK (via ZMP) |
| Mechanism | Transcriptional reprogramming | Allosteric AMPK activation |
| Route | Oral bioavailability | Subcutaneous/IV |
| Side effects | Unknown human | Hyperuricemia, WADA-banned |
| Tissue specificity | Primarily muscle | Broad AMPK activation |
| Duration of effect | Sustained (days) | Short (hours) |
AICAR activates AMPK acutely — it basically tells cells "you're out of energy, adapt accordingly." SLU-PP-332 reprograms the transcription that AMPK normally coordinates — a more durable, more targeted intervention.
The animal data in more detail
Billon et al., 2023 (original characterization):
- Sedentary mice given SLU-PP-332 ran ~50% farther on graded treadmill test
- Muscle fiber typing shifted toward Type I (slow-twitch, oxidative)
- Mitochondrial DNA copy number increased ~40%
- PGC-1α target genes significantly upregulated
Xu et al., 2023 (metabolic effects):
- Obese mice on high-fat diet showed 10–12% body fat reduction
- Food intake unchanged versus controls
- Blood glucose and insulin sensitivity improved significantly
- Liver fat reduced ~25%
Follow-up 2024 studies:
- Combined with actual exercise, effects were additive (not redundant)
- No cardiac hypertrophy at tested doses (unlike some earlier ERR compounds)
- No obvious reproductive toxicity at clinically-relevant doses
What we don't know
The critical unknowns about SLU-PP-332 in humans:
1. Does it translate? Many exercise-mimetic candidates have shown dramatic animal effects that failed to translate. PPAR-δ agonists, sirtuin activators, and several AMPK drugs all had similar "exercise in a pill" headlines that didn't hold up in humans.
2. ERR-β and ERR-γ effects. SLU-PP-332 is pan-ERR — it activates all three. β and γ isoforms have tissue distributions and functions that aren't fully characterized. Activating them systemically may have consequences we don't know yet.
3. Dose-response and long-term safety. Animal studies cover weeks. Humans use drugs for years. ERR signaling affects multiple organ systems; chronic pan-ERR activation is an untested intervention.
4. Reproductive effects. ERRs are involved in placental function and reproductive tissue homeostasis. Women of reproductive age may face meaningful concerns that preclinical models don't capture.
5. Performance enhancement ethics and regulation. If SLU-PP-332 ever reached humans and showed exercise-mimetic effects, it would be immediately added to WADA's prohibited list. Expect that to happen preemptively before any clinical approval.
Current regulatory status
As of April 2026, SLU-PP-332:
- Is not a peptide — it's a small molecule
- Has no Investigational New Drug (IND) application on file
- Has no clinical trials in humans
- Is not being actively developed by a major pharma company as of public record
- Is sold by some research-chemical suppliers labeled "for research use only"
The research-chemical availability is concerning. Using a compound with zero human exposure data, no supplier-level quality standards, and no known dose-response relationship is substantially riskier than using better-characterized research peptides.
If you're considering it anyway
SLU-PP-332 is at the extreme end of the risk spectrum for research compounds. Specifically:
- No human data = you are literally in Phase 0
- Small molecule purity is harder to verify than peptide identity
- Effect on multiple tissues beyond muscle is uncharacterized
- Long-term effects are completely unknown
- No reversal strategy if something goes wrong
These factors place it below most research peptides on the risk/benefit scale. Researchers should treat it as an investigative compound, not a performance aid.
Why researchers care anyway
Despite all those caveats, SLU-PP-332 matters for three reasons:
1. It validates the ERR target. If an ERR agonist can produce these effects reproducibly in mammals, then pharmaceutical-grade ERR drugs will eventually be developed — by a company, not a random supplier.
2. It suggests exercise mimetic science is real. Many mimetic candidates have failed. SLU-PP-332's effects are more robust and more mechanistically coherent than several previous candidates.
3. It opens questions about "exercise adaptation without exercise." Is that even desirable? For sarcopenia patients or people with severe disability, yes. For healthy people, probably not — because exercise has benefits beyond muscle mitochondria that an ERR agonist won't replicate.
What to watch for
- Any legitimate pharmaceutical company picking up ERR agonism as a clinical target
- Publication of long-term animal studies (>6 months) showing safety
- First-in-human trials — these will likely be in muscle-wasting conditions, not healthy volunteers
- Related compounds with improved selectivity (ERR-α selective, for instance)
Read next: SLU-PP-332 peptide profile, or AICAR profile for the older exercise-mimetic comparison.
PEPGAINS RESEARCH
Independent peptide research, read by 8,400 researchers. Every claim cited, every affiliate disclosed.